Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify plasma-based biomarkers that could indicate a person’s likelihood of developing Parkinson’s disease (PD) many years before clinical diagnosis.

News Medical

United States

Grifols receives grant for early Parkinson's disease biomarker discovery

Ad Fontes Media

Media Bias/Fact Check

Ian Birkby

A 47-year-old man was the first in the world to be treated outside of a study context with a new technique for the symptoms of Parkinson's disease in Amsterdam this week, Amsterdam UMC reported. The technique is called Adaptive DBS (aDBS) and gives pulses (shocks) to the brain when it is needed.

NL Times

Amsterdam UMC uses new treatment for Parkinson’s disease for the first time on a patient

The actor’s charitable foundation has just unlocked the key to flagging Parkinson’s disease early, putting us one step closer to ending Parkinson’s for good.

goodgoodgood.co

Michael J. Fox funds new diagnostic testing that could detect Parkinson's 'even before symptoms appear'

The newly announced sham surgery-controlled trial will include 102 patients with moderate PD testing several end points, such as change in ON-time without troublesome dyskinesia, over a 78-week period.

neurologylive.com

Cell Therapy Bemdaneprocel Advances to Phases 3 Registrational Trial in Parkinson Disease

The Corner Link Securities | The Catalan blood products company has received a $21 million grant from the Michael J. Fox Foundation (MJFF) for Parkinson’s Disease Research to identify plasma-based biomarkers that could indicate a person’s likelihood of developing Parkinson’s disease (PD) “many years before” clinical diagnosis. The initiative, dubbed ‘Chronos PD’, could accelerate the discovery of new diagnostic tools, as well as the identificati…

The Corner

Michael J. Fox Foundation donates Grifols $21 million to research new diagnostic tools for Parkinson's disease

BlueRock plans to start a Phase 3 trial of bemdaneprocel in moderate Parkinson’s disease in the first half of 2025.

Parkinson's News Today

Bemdaneprocel to move into Phase 3 trial soon

Grifols has received a $21 million (€20.49 million) grant from the Michael J. Fox Foundation for Parkinson’s Disease Research (MJFF) to conduct a pioneering study to detect early signs of Parkinson ‘s in plasma samples . In a statement on Tuesday, the company explained that the aim of the study is to identify plasma-based biomarkers that could indicate the likelihood of a person developing the disease many years before their clinical diagnosis. …

Grifols receives grant for early Parkinson's disease biomarker discovery

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics